Income statement
USD
Annual
| Metric | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 2M | 0 | 0 | 0 |
| Gross Profit | 1M | 0 | 0 | 0 |
| Operating Income | -7M | -1M | -2M | -467K |
| EBITDA | -7M | -561K | -2M | -605K |
| Net Income | -7M | -1M | 205K | -329K |
| EPS (Diluted) | — | — | — | — |
Financial Services
Live Price
Offline$0.26
-7.14% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alpha Healthcare Acquisition Corp. III (ALPAW) is a Financial Services stock. The stock last traded around $0.26. Baseline metrics include revenue growth of 0.0%, EPS growth of -7615.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -7615.7%, free cash flow +23.8% with operating margin -371.6% and ROIC 130.3%. Valuation already assumes a fairly strong business story at price/sales 101.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ALPAW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ALPAW
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ALPAW Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ALPAW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$329.4K
-260.7% YoY
Free Cash Flow
-$451.2K
+7.7% YoY
Revenue Growth
+0.0%
EPS Growth
-7615.7%
Gross Margin
57.2%
Net Margin
-361.0%
Income statement
USD
| Metric | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 2M | 0 | 0 | 0 |
| Gross Profit | 1M | 0 | 0 | 0 |
| Operating Income | -7M | -1M | -2M | -467K |
| EBITDA | -7M | -561K | -2M | -605K |
| Net Income | -7M | -1M | 205K | -329K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|
| Cash & Equivalents | 707K | 157K | 188K | 774K |
| Total Assets | 2M | 1M | 157M | 155M |
| Total Liabilities | 8M | 6M | 7M | 6M |
| Shareholder Equity | -6M | -5M | 150M | 150M |
| Total Debt | 310K | 398K | 0 | 0 |
| Net Debt | -397K | 241K | -188K | -774K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
451K
+7.7% YoY
Capital Expenditures
0
Free Cash Flow
451K
+7.7% YoY
Key ratios
Gross Margin
57.2%
Operating Margin
-371.6%
Net Margin
-361.0%
ROE
158.9%
Debt / Equity
-0.05x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.